Trial Profile
A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Mar 2022
Price :
$35
*
At a glance
- Drugs MEDI-2228 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Acronyms MEDI2228
- Sponsors AstraZeneca; MedImmune
- 25 Mar 2022 Status changed from active, no longer recruiting to completed.
- 11 Feb 2022 Planned End Date changed from 30 Jun 2022 to 21 Mar 2022.
- 11 Feb 2022 Planned primary completion date changed from 30 Jun 2022 to 21 Mar 2022.